Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma

✍ Scribed by Mark Baguma-Nibasheka; Christie Barclay; Audrey W. Li; Laurette Geldenhuys; Geoffrey A. Porter; Jonathan Blay; Alan G. Casson; Paul R. Murphy

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 345 KB
• Volume: 46
• Category: Article
• ISSN: 0899-1987
• DOI: 10.1002/mc.20339

✦ Synopsis

Abstract

Inhibition of cyclooxygenase (COX)‐2 is reported to suppress growth and induce apoptosis in human esophageal adenocarcinoma (EADC) cells, although the precise biologic mechanism is unclear. In this study we tested the hypothesis that the antitumor activity of COX‐2 inhibitors may involve modulation of basic fibroblast growth factor (FGF‐2), which is overexpressed in EADC. We evaluated the effects of NS‐398, a selective COX‐2 inhibitor, on FGF‐2 expression and proliferation of EADC cell lines that express COX‐2 and those that do not. We also correlated COX‐2 and FGF‐2 expression with clinico‐pathologic findings and outcome in a well‐characterized series of surgically resected EADC tissues. Seg‐1 cells robustly expressed COX‐2 and FGF‐2, whereas Bic‐1 cells expressed neither transcript. FGF‐2 was reduced to undetectable levels in Seg‐1 cells following NS‐398 treatment, but increased within 4 h of drug removal. NS‐398 significantly inhibited the growth of Seg‐1 cells, and this effect was ameliorated by addition of exogenous FGF‐2. In contrast, NS‐398 had no effect on Bic‐1 cell proliferation and FGF‐2 alone had no effect on proliferation of either cell line. NS‐398, or a neutralizing anti‐FGF‐2 antibody, induced apoptosis in Seg‐1 cells, and these effects were inhibited by addition of exogenous FGF‐2. COX‐2 protein was strongly expressed in 46% (10/22) of EADCs, and was associated with a trend towards reduced disease‐free survival. These findings indicate that the antitumor effects of COX‐2 inhibition in EADC cells may be mediated via suppression of FGF‐2, and that COX‐2 may be a clinically relevant molecular marker in the management of human EADC. © 2007 Wiley‐Liss, Inc.